350 related articles for article (PubMed ID: 22632597)
21. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
Stock I
Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
[TBL] [Abstract][Full Text] [Related]
22. Carbapenemase-Producing Enterobacteriaceae and Nonfermentative Bacteria, the Philippines, 2013-2016.
Velasco JM; Valderama MT; Peacock T; Warawadee N; Nogrado K; Navarro FC; Chua D; Apichai S; Sirigade R; Macareo LR; Swierczewski B
Emerg Infect Dis; 2017 Sep; 23(9):1597-1598. PubMed ID: 28820383
[TBL] [Abstract][Full Text] [Related]
23. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management.
Temkin E; Adler A; Lerner A; Carmeli Y
Ann N Y Acad Sci; 2014 Sep; 1323():22-42. PubMed ID: 25195939
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and mechanisms of resistance to carbapenems in Enterobacteriaceae isolates from 24 hospitals in Belgium.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y;
J Antimicrob Chemother; 2013 Aug; 68(8):1832-7. PubMed ID: 23557926
[TBL] [Abstract][Full Text] [Related]
25. [Laboratory detection of carbapenemase-producing Enterobacteriaceae].
Cercenado E
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():8-11. PubMed ID: 26365726
[TBL] [Abstract][Full Text] [Related]
26. Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010.
Castanheira M; Deshpande LM; Farrell SE; Shetye S; Shah N; Jones RN
Diagn Microbiol Infect Dis; 2013 Feb; 75(2):210-3. PubMed ID: 23177221
[TBL] [Abstract][Full Text] [Related]
27. Carbapenemases in Enterobacteriaceae: types and molecular epidemiology.
Martínez-Martínez L; González-López JJ
Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():4-9. PubMed ID: 25542046
[TBL] [Abstract][Full Text] [Related]
28. ESBL- and Carbapenemase-Producing Enterobacteriaceae in Patients with Bacteremia, Yangon, Myanmar, 2014.
Myat TO; Hannaway RF; Zin KN; Htike WW; Win KK; Crump JA; Murdoch DR; Ussher JE
Emerg Infect Dis; 2017 May; 23(5):857-859. PubMed ID: 28418298
[TBL] [Abstract][Full Text] [Related]
29. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
30. NDM-1, OXA-48 and OXA-181 carbapenemase-producing Enterobacteriaceae in Sultanate of Oman.
Dortet L; Poirel L; Al Yaqoubi F; Nordmann P
Clin Microbiol Infect; 2012 May; 18(5):E144-8. PubMed ID: 22404169
[TBL] [Abstract][Full Text] [Related]
31. Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae.
Gazin M; Paasch F; Goossens H; Malhotra-Kumar S;
J Clin Microbiol; 2012 Apr; 50(4):1140-6. PubMed ID: 22259207
[TBL] [Abstract][Full Text] [Related]
32. Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals.
Williamson DA; Sidjabat HE; Freeman JT; Roberts SA; Silvey A; Woodhouse R; Mowat E; Dyet K; Paterson DL; Blackmore T; Burns A; Heffernan H
Int J Antimicrob Agents; 2012 Jun; 39(6):529-33. PubMed ID: 22526013
[TBL] [Abstract][Full Text] [Related]
33. Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed.
Khan AU; Nordmann P
Scand J Infect Dis; 2012 Jul; 44(7):531-5. PubMed ID: 22497308
[TBL] [Abstract][Full Text] [Related]
34. Global spread of New Delhi metallo-β-lactamase 1.
Bogaerts P; Verroken A; Jans B; Denis O; Glupczynski Y
Lancet Infect Dis; 2010 Dec; 10(12):831-2. PubMed ID: 21109171
[No Abstract] [Full Text] [Related]
35. Investigation of VIM, IMP, NDM-1, KPC AND OXA-48 enzymes in Enterobacteriaceae strains.
Demir Y; Zer Y; Karaoglan I
Pak J Pharm Sci; 2015 May; 28(3 Suppl):1127-33. PubMed ID: 26051720
[TBL] [Abstract][Full Text] [Related]
36. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.
Logan LK; Weinstein RA
J Infect Dis; 2017 Feb; 215(suppl_1):S28-S36. PubMed ID: 28375512
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Bahrain.
Bindayna KM; Senok AC; Jamsheer AE
J Infect Public Health; 2009; 2(3):129-35. PubMed ID: 20701872
[TBL] [Abstract][Full Text] [Related]
38. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015.
Albiger B; Glasner C; Struelens MJ; Grundmann H; Monnet DL;
Euro Surveill; 2015; 20(45):. PubMed ID: 26675038
[TBL] [Abstract][Full Text] [Related]
39. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
40. Carbapenem-resistant enterobacteriaceae: an emerging problem in children.
Logan LK
Clin Infect Dis; 2012 Sep; 55(6):852-9. PubMed ID: 22700827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
